We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Needs Ongoing, Public Approach To Risk-Benefit Assessments: IOM
FDA Needs Ongoing, Public Approach To Risk-Benefit Assessments: IOM
May 4, 2012
The FDA needs to take an ongoing, lifecycle approach to assessing the risk-benefit profiles of new drugs and should seek more public input during the process, a new Institute of Medicine (IOM) report urges.